Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Carlile DJ, et al. Among authors: bayliss mk. Br J Clin Pharmacol. 1999 Jun;47(6):625-35. doi: 10.1046/j.1365-2125.1999.00935.x. Br J Clin Pharmacol. 1999. PMID: 10383540 Free PMC article.
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. Barter ZE, et al. Among authors: bayliss mk. Curr Drug Metab. 2007 Jan;8(1):33-45. doi: 10.2174/138920007779315053. Curr Drug Metab. 2007. PMID: 17266522 Review.
The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.
Somers GI, Bayliss MK, Houston JB. Somers GI, et al. Among authors: bayliss mk. Xenobiotica. 2007 Aug;37(8):855-69. doi: 10.1080/00498250701474058. Xenobiotica. 2007. PMID: 17701833
The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.
Somers GI, Harris AJ, Bayliss MK, Houston JB. Somers GI, et al. Among authors: bayliss mk. Xenobiotica. 2007 Aug;37(8):832-54. doi: 10.1080/00498250701485575. Xenobiotica. 2007. PMID: 17701832
Isolation and culture of human hepatocytes.
Bayliss M, Somers G. Bayliss M, et al. Methods Mol Med. 2005;107:249-67. doi: 10.1385/1-59259-861-7:249. Methods Mol Med. 2005. PMID: 15492377 No abstract available.
A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development.
Cross DM, Bayliss MK. Cross DM, et al. Among authors: bayliss mk. Drug Metab Rev. 2000 May;32(2):219-40. doi: 10.1081/dmr-100100574. Drug Metab Rev. 2000. PMID: 10774777 Review.
7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions.
Bayliss MK, Bell JA, Wilson K, Park GR. Bayliss MK, et al. Xenobiotica. 1994 Mar;24(3):231-41. doi: 10.3109/00498259409043235. Xenobiotica. 1994. PMID: 8009886
A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes.
Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR. Somers GI, et al. Among authors: bayliss mk. Drug Metab Dispos. 2007 Oct;35(10):1797-805. doi: 10.1124/dmd.107.015966. Epub 2007 Jul 12. Drug Metab Dispos. 2007. PMID: 17627976
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
Bayliss MK, Butler J, Feldman PL, Green DV, Leeson PD, Palovich MR, Taylor AJ. Bayliss MK, et al. Drug Discov Today. 2016 Oct;21(10):1719-1727. doi: 10.1016/j.drudis.2016.07.007. Epub 2016 Jul 14. Drug Discov Today. 2016. PMID: 27423371 Review.
Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery.
Spalding DJ, Harker AJ, Bayliss MK. Spalding DJ, et al. Among authors: bayliss mk. Drug Discov Today. 2000 Dec 1;5(12 Suppl 1):70-76. doi: 10.1016/s1359-6446(00)00061-1. Drug Discov Today. 2000. PMID: 11564569
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page